INMB Inmune Bio, Inc.

Nasdaq inmunebio.com


$ 1.83 $ -0.03 (-1.61 %)    

Monday, 13-Oct-2025 15:59:52 EDT
QQQ $ 601.81 $ 12.51 (2.12 %)
DIA $ 460.92 $ 5.81 (1.28 %)
SPY $ 662.71 $ 10.02 (1.53 %)
TLT $ 90.54 $ -0.05 (-0.06 %)
GLD $ 379.71 $ 8.97 (2.43 %)
$ 1.83
$ 1.89
$ 1.80 x 1,405
$ 2.06 x 5,000
$ 1.82 - $ 1.90
$ 1.71 - $ 11.64
475,886
na
42.64M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-11-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inmune-bio-submits-manuscript-detailing-results-of-phase-2-mindful-trial-to-nature-portfolio-journal-npj-dementia

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manu...

 inmune-bio-completes-first-full-scale-pilot-commercial-manufacturing-run-of-cordstrom-umbilical-cord-tissue-derived-mesenchymal-stromal-cell-therapy-for-treatment-of-rdeb

INmune Bio Inc. (NASDAQ:INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company...

 correction-inmune-bio-q2-adj-eps-034-beats-039-estimate

INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by...

Core News & Articles

https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8

 inmune-bios-inkmune-meets-primary-and-secondary-endpoints-in-phase-iii-trial-for-metastatic-prostate-cancer

 INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to rep...

Core News & Articles

INmune Bio Inc. (NASDAQ:INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial eva...

 inmune-bio-rebounds-sharply-during-after-hours-trading-whats-driving-the-surge

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

 inmune-bio-to-present-new-phase-2-data-on-alzheimers-drug-xpro-at-aaic-on-july-29

INmune Bio Inc. (NASDAQ:INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel...

 pharma-bro-martin-shkreli-says-good-chance-inmune-bio-stock-will-slip-90-on-monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days...

 pharma-bro-martin-shkreli-says-good-chance-inmune-bio-stock-will-slip-90-on-monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days...

 maxim-group-maintains-buy-on-inmune-bio-lowers-price-target-to-8

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $30 to $8.

 btig-downgrades-inmune-bio-to-neutral

BTIG analyst Thomas Shrader downgrades INmune Bio (NASDAQ:INMB) from Buy to Neutral.

 scotiabank-downgrades-inmune-bio-to-sector-underperform-lowers-price-target-to-06

Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:INMB) from Sector Outperform to Sector Underperform and lower...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION